Table 1 Comparison of baseline characteristics between the two Groups.
Group | |||||||
|---|---|---|---|---|---|---|---|
D-TACE + Donafenib + Tislelizumab group (N = 51) | D-TACE + Sorafenib group (N = 54) | Chi-Square Tests(p-value) | t-test(p-value) | ||||
Fisher’s Exact Test | Pearson Chi-Square | ||||||
Gender | Female | Count(%) | 12(23.5%) | 11(20.4%) | 0.814 | ||
Male | Count(%) | 39(76.5%) | 43(79.6%) | ||||
Etiology of cirrhosis | Hepatitis B | Count(%) | 42(82.4%) | 43(79.6%) | 0.797 | ||
Hepatitis C | Count(%) | 5(9.8%) | 6(11.1%) | ||||
Alcoholic | Count(%) | 2(3.9%) | 4(7.4%) | ||||
others | Count(%) | 2(3.9%) | 1(1.9%) | ||||
Pre-treatment ECOG | 0 | Count(%) | 16(31.4%) | 20(37.0%) | 0.811 | ||
1 | Count(%) | 26(51.0%) | 26(48.1%) | ||||
2 | Count(%) | 9(17.6%) | 8(14.8%) | ||||
Pre-treatment liver function | Child A | Count(%) | 29(56.9%) | 32(59.3%) | 0.845 | ||
Child B | Count(%) | 22(43.1%) | 22(40.7%) | ||||
BCLC staging | B | Count(%) | 14(27.5%) | 17(31.5%) | 0.675 | ||
C | Count(%) | 37(72.5%) | 37(68.5%) | ||||
Portal vein tumor thrombus | No | Count(%) | 20(39.2%) | 25(46.3%) | 0.555 | ||
Yes | Count(%) | 31(60.8%) | 29(53.7%) | ||||
AFP | < 400ug/L | Count(%) | 13(25.5%) | 10(18.5%) | 0.481 | ||
≥ 400ug/L | Count(%) | 38(74.5%) | 44(81.5%) | ||||
Age(Years) | Mean ± SD | 56.6 ± 11.5 | 52.8 ± 12.1 | 0.109 | |||
Pre-treatment bilirubin(µmol/L) | Mean ± SD | 15.84 ± 6.50 | 14.54 ± 6.88 | 0.321 | |||
Pretreatment AST(U/L) | Mean ± SD | 49.9 ± 27.0 | 46.9 ± 23.3 | 0.538 | |||
Pretreatment ALT(U/L) | Mean ± SD | 50.6 ± 25.1 | 53.1 ± 26.2 | 0.618 | |||
Pretreatment WBC(G/L) | Mean ± SD | 4.61 ± 1.66 | 4.33 ± 1.25 | 0.321 | |||
Pretreatment RBC(T/L) | Mean ± SD | 3.68 ± 1.55 | 3.55 ± 1.47 | 0.657 | |||
Pretreatment PLT(G/L) | Mean ± SD | 108.0 ± 56.7 | 111.8 ± 39.8 | 0.691 | |||
